Stock Market

For portfolio exposure to the data analytics, cybersecurity and artificial intelligence (AI) industries, you may be considering Palantir Technologies (NYSE:PLTR) stock right now. That’s understandable, but be careful. Investing in Palantir during a time of AI-market exuberance may be a costly mistake.  Don’t get the wrong idea. It could be a great idea to buy Palantir stock
0 Comments
In the fast-paced world of tech investments, finding the next big hit is like navigating a complex maze. Amidst this landscape, a few standout stocks emerge as potential game-changers, each poised to potentially turn your investments into millions. These millionaire-maker tech stocks stand out with their compelling narratives of innovation, collaboration, and performance excellence. Moreover,
0 Comments
Finding millionaire-maker stocks could be likened to finding a needle in a haystack! The upcoming decade may be turbulent. Not only will we grapple with a building geopolitical tension globally. But also, worries stemming from climate change and economic malaise are pressing. It’s a sentiment that’s been a subject of concern, reflected from the ongoing
0 Comments
The stock market will always have good investment opportunities. As investors, it’s our job to establish filtering criteria that we utilize for weeding out the duds. Consider analyzing and potentially adding these three penny stocks to your first-quarter portfolio. Let’s take a quick look. Blink Charging (BLNK) Source: David Tonelson/Shutterstock.com Blink Charging (NASDAQ:BLNK) is booming
0 Comments
With the artificial intelligence (AI) buzz capturing global attention, discerning investors must identify stocks with concrete revenue gains from AI. Analysts project the AI revolution as the fourth industrial revolution, foreseeing widespread applications across industries. Notable sectors like cybersecurity have successfully employed AI for threat detection, showcasing its potential beyond early adopters like Google. That
0 Comments
For many biotech stocks, price and performance hinges on the success of a drug in testing. This means most biotech companies rely on one market opportunity to succeed financially. Testing usually takes several years, with many different criteria to meet before applying for review by regulators. Even after successful tests, the survival of these stocks
0 Comments